Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-10-18 DOI:10.1080/14760584.2024.2417393

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2417393","DOIUrl":null,"url":null,"abstract":"Objectives: It is important to assess healthcare providers (HCPs) knowledge, attitudes, perceptions, and preferences towards new pneumococcal vaccines for adults.Methods: HCPs who met eligibility criteria completed an online survey between March - May 2024 that included a discrete choice experiment (DCE) to elicit preferences.Results: Among 340 participating HCPs, the average age was 44.9 years old, and the majority were male (55.6%), and White (85.3%). Most HCPs reported that they would support (90.3%) and implement (91.5%) a lower age-based recommendation for pneumococcal vaccines (from adults 65+ years to adults 50+ years). A majority of HCPs would offer a supplemental dose of a pneumococcal vaccine to high-risk adults 19-49 years, at-risk or high-risk adults 50-64 years, and adults 65+ years regardless of risk status to increase protection after completing the recommended series. DCE results showed that coverage of pneumococcal pneumonia and invasive pneumococcal disease (IPD) in adults 65+ years were the two most important attributes in evaluating pneumococcal vaccines.Conclusions: HCPs preferred a pneumococcal vaccine with increased coverage against pneumococcal pneumonia and IPD, and they supported lowering the age recommendation for pneumococcal vaccination as well as a supplemental vaccine dose to provide additional coverage for adults.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2417393","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: It is important to assess healthcare providers (HCPs) knowledge, attitudes, perceptions, and preferences towards new pneumococcal vaccines for adults.

Methods: HCPs who met eligibility criteria completed an online survey between March - May 2024 that included a discrete choice experiment (DCE) to elicit preferences.

Results: Among 340 participating HCPs, the average age was 44.9 years old, and the majority were male (55.6%), and White (85.3%). Most HCPs reported that they would support (90.3%) and implement (91.5%) a lower age-based recommendation for pneumococcal vaccines (from adults 65+ years to adults 50+ years). A majority of HCPs would offer a supplemental dose of a pneumococcal vaccine to high-risk adults 19-49 years, at-risk or high-risk adults 50-64 years, and adults 65+ years regardless of risk status to increase protection after completing the recommended series. DCE results showed that coverage of pneumococcal pneumonia and invasive pneumococcal disease (IPD) in adults 65+ years were the two most important attributes in evaluating pneumococcal vaccines.

Conclusions: HCPs preferred a pneumococcal vaccine with increased coverage against pneumococcal pneumonia and IPD, and they supported lowering the age recommendation for pneumococcal vaccination as well as a supplemental vaccine dose to provide additional coverage for adults.

查看原文本刊更多论文

美国医疗服务提供者对成人肺炎球菌疫苗的偏好和态度。

目标：评估医疗保健提供者（HCP）对成人新肺炎球菌疫苗的认识、态度、看法和偏好非常重要：方法：符合资格标准的医疗保健提供者（HCPs）在 2024 年 3 月至 5 月期间完成了一项在线调查，其中包括一项离散选择实验（DCE）以了解偏好：在 340 名参与调查的初级保健医生中，平均年龄为 44.9 岁，大多数为男性（55.6%）和白人（85.3%）。大多数保健医生表示，他们将支持（90.3%）并实施（91.5%）降低肺炎球菌疫苗的年龄建议（从 65 岁以上成人降至 50 岁以上成人）。大多数初级保健医生会为 19-49 岁的高风险成人、50-64 岁的高风险或高风险成人以及 65 岁以上的成人（无论其风险状况如何）提供一剂补充肺炎球菌疫苗，以在完成推荐的系列接种后提高保护率。DCE 结果显示，肺炎球菌肺炎和 65 岁以上成人侵袭性肺炎球菌疾病 (IPD) 的覆盖率是评估肺炎球菌疫苗的两个最重要的属性：HCPs更倾向于接种能提高肺炎球菌肺炎和侵入性肺炎球菌疾病覆盖率的肺炎球菌疫苗，他们支持降低肺炎球菌疫苗接种的年龄建议，以及补充疫苗剂量以提高成人的覆盖率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.